

Summer 2008

In This Issue

AACR, ACRIN, ASCO, ASCO Gastrointestinal Cancers Symposium, ASCO Genitourinary Cancers Symposium, SGO, and Others

Cooperative Group Abstracts:

- [Breast Cancer](#)
- [CNS Cancer](#)
- [Gastrointestinal Cancer](#)
- [Genitourinary Cancer](#)
- [Gynecologic Cancer](#)
- [Head and Neck Cancer](#)
- [Leukemia, Myelodysplasia, and Transplantation](#)
- [Lymphoma and Plasma Cell Disorders](#)
- [Lung Cancer](#)
- [Melanoma Skin Cancers](#)
- [Sarcoma/Bone and Soft Tissue Cancers](#)
- [Other Cancer](#)

NCI/CTEP Abstracts & Activities:

- [DCTD/DCP Abstracts](#)
- [DCTD and DCP Activities](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

COG ANBL00B1: The ALK gene, a known oncogene previously associated with anaplastic large cell lymphoma and a subset of lung cancers, was shown to be the cause of most cases of familial neuroblastoma. Moreover, ALK genomic alterations, including gene amplification and activating point mutations, were demonstrated as somatic changes in a subset of high-risk neuroblastoma tumors. These discoveries have obvious therapeutic implications, as small molecule inhibitors of ALK have entered clinical evaluations in adults with cancer. (*Other Cancer/COG/ Mosse et al.*)

COG AEWS0031: Standard therapy for patients with localized Ewing sarcoma family tumors (ESFT) previously consisted of every 3 week administration of either vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide. Intensification of therapy was achieved by compressing the interval of chemotherapy administration to every 2 weeks. This resulted in a statistically significant improvement in the 3 year EFS from 65% (std timing) as compared to 76% (compressed timing) (p=0.028) in this prospectively randomized trial. Improvements continue to be seen in patients with localized EFS. (*Sarcoma/Bone and Soft Tissue Cancers/COG/Womer et al.*)



Cancer Trials Support Unit
A SERVICE OF THE NATIONAL CANCER INSTITUTE
Linking practice to progress



CureSearch
Children's Oncology Group

ACOSOG

NSABP
National Surgical Adjuvant Breast and Bowel Project



Eastern Cooperative Oncology Group

RTOG
RADIATION THERAPY ONCOLOGY GROUP



Southwest Oncology Group
A National Clinical Research Group

NCCTG
NORTH CENTRAL CANCER TREATMENT GROUP
Working with Mayo Clinic to bring the latest cancer research to the community

National Cancer Institute of Canada
Institut national du cancer du Canada
Clinical Trials Group
Groupe des essais cliniques



Cooperative Group Abstracts

Breast Cancer

ACOSOG

Hawes D, Patel M, Hunt KK, Giuliano AE, Cote RJ: Prevalence of putative breast cancer stem cells (BCSC) in lymph node occult metastases (LNOM) of patients with node-negative (LN-) breast cancer (BC). J Clin Oncol 2008; 26(Suppl):Abst.1069.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35335

Protocol(s): ACOSOG-Z0010

ACRIN

Berg W: Breast Imaging: When to Implement & Ultrasound and Magnetic Resonance Imaging (MRI) in Breast Cancer Screening. Avon Foundation Breast Cancer Forum, Houston, Texas, Feb, 2008.

<http://www.crusadeforum.org/>

Protocol(s): ACRIN-6666

Bolan P: Design of Quality Control Measures for a Multi-site Clinical Trial of Breast MRS-ACRIN 6657. International Society for Magnetic Resonance in Medicine (ISMRM), Toronto, Canada, May, 2008.

<http://www.ismrm.org/08/index.htm>

Protocol(s): ACRIN-6657

CALGB

Muss HB, Berry DL, Cirincione C, Theodoulou M, Mauer A, Cohen H, Partridge AH, Norton L, Hudis CA, Winer EP: Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. J Clin Oncol 2008; 26(Suppl):Abst.507.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30857

Protocol(s): CALGB-49907

Partridge AH, Archer LE, Kornblith AB, Gralow JR, Grenier D, Perez EA, Wolff AC, Hudis CA, Winer EP, Muss H: CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. J Clin Oncol 2008; 26(Suppl):Abst.6542.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35417

Protocol(s): CALGB-49907

Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, Winer EP, Hudis CA, Isaacs C, Weckstein D, Schilsky RL, Paskett E: Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809. J Clin Oncol 2008; 26(Suppl):Abst.512.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31982

Protocol(s): CALGB-79809

ECOG

Goldstein LJ, Gray RJ, Bugarini R, Shak S, Badve SS, Baehner FL, Davidson NE, Sledge GW, Sparano JA: Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. *J Clin Oncol* 2008; 26(Suppl):Abst.557.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33166
Protocol(s): E2197

Klencke BJ, Bhattacharya S, Samant MK, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE, Miller KD: Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). *J Clin Oncol* 2008; 26(Suppl):Abst.1036.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33989
Protocol(s): E2100

Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW: Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). *J Clin Oncol* 2008; 26(Suppl):Abst.520.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30295
Protocol(s): E2104

NCCTG

Bardia A, Novotny PJ, Sloan JA, Barton DL, Steen PD, Watson C, Christensen B, Loprinzi CL: Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis. *J Clin Oncol* 2008; 26(Suppl):Abst.9595.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35739
Protocol(s): Multiple Trials

Goetz MP, Moyer AM, Weinshilboum RM, Suman VA, Hebringer SJ, Ames MM, Berg JC, Reynolds C, Perez EA, Ingle JN: Role of SULT1A1 copy number in tamoxifen treated breast cancer: Findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. *J Clin Oncol* 2008; 26(Suppl):Abst.22041.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32705
Protocol(s): NCCTG-89-30-52

Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner EG, Loprinzi CL, Atherton PJ, Carlson MD, Salim M, Perez EA: N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). *J Clin Oncol* 2008; 26(Suppl):Abst.525.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30232
Protocol(s): N02C1

Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM, Goetz MP, Perez EA: N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol 2008; 26(Suppl):Abst.1081.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35549

Protocol(s): N0436

Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL: N03CC--a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J Clin Oncol 2008; 26(Suppl):Abst.564.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35657

Protocol(s): N03CC

Moreno-Aspitia A, Dueck AC, Lingle WL, Kutteh L, Tenner K, Davidson NE, Martino S, Kaufman P, Carney WP, Perez EA: Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 2008; 26(Suppl):Abst.529.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35184

Protocol(s): N9831

Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA: Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). J Clin Oncol 2008; 26(Suppl):Abst.1063.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35315

Protocol(s): N0437

Reinholz MM, Dueck AC, Lingle WL, Allen Ziegler KL, Wiktor AE, Paik S, Jenkins RB, Perez EA: The concordance between NCCTG's and NSABP's C-myc FISH assays. J Clin Oncol 2008; 26(Suppl):Abst.22110.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35214

Protocol(s): NSABP-B-31, N9831

Roy V, Pockaj BA, Northfelt DW, Allred JB, Liu H, Nikcevich DA, Mattar BI, Perez EA: N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol 2008; 26(Suppl):Abst.563.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31083

Protocol(s): N0338

NCIC Clinical Trials Group

Burnell MJ, O'Connor EM, Chapman JW, Levine MN, Pritchard KI, O'Brien PS, Howarth KJ, Ding Z, Whelan TJ, Shepherd LE: Triple-negative receptor status and prognosis in the NCIC CTG MA.21 adjuvant breast cancer trial. J Clin Oncol 2008; 26(Suppl):Abst.550.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33209

Protocol(s): NCIC-MA.12

NSABP

Cronin WM, Cecchini RS, Wickerham DL, Vogel VG, Costantino JP, Wolmark N: Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR). J Clin Oncol 2008; 26(Suppl):Abst.6518.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35746
Protocol(s): NSABP-P-2

Julian TB, Land SR, Wang Y, Vicini F, Arthur D, Mamounas EP, Costantino JP, Wolmark N: Is boost therapy necessary in the treatment of DCIS? J Clin Oncol 2008; 26(Suppl):Abst.537.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35097
Protocol(s): NSABP-B-24

Land SR, Kopec JA, Lee M, Haile SR, Ritter MW, Krag D, Anderson SJ, Ganz PA, Wolmark N: Quality of life in breast cancer patients receiving sentinel-node (SN) biopsy alone or with axillary dissection (AD): Results from NSABP Protocol B-32. J Clin Oncol 2008; 26(Suppl):Abst.9533.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35171
Protocol(s): NSABP-B-32

Reinholz MM, Dueck AC, Lingle WL, Allen Ziegler KL, Wiktor AE, Paik S, Jenkins RB, Perez EA: The concordance between NCCTG's and NSABP's C-myc FISH assays. J Clin Oncol 2008; 26(Suppl):Abst.22110.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35214
Protocol(s): N9831, NSABP-B-31

Wang J, Anderson SJ, Costantino JP, Mamounas EP, Hassett JM, Wolmark N: Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system? J Clin Oncol 2008; 26(Suppl):Abst.11037.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31134
Protocol(s): NSABP-B-25, NSABP-B-22, NSABP-B-28, NSABP-B-31

SWOG

Kash J, Barlow WE, Albain KS, Gralow JR, Lew D, Flaherty LE, Royce ME, Hortobagyi GN, Livingston RB: Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. J Clin Oncol 2008; 26(Suppl):Abst.1033.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33986
Protocol(s): S0102

CNS Cancer

NCCTG

Brown PD, Krishnan S, Sarkaria J, Wu W, Mischel P, Yong WH, Arusell R, Jenkins RB, Buckner JC, Giannini C: A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). J Clin Oncol 2008; 26(Suppl):Abst.2016.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31388
Protocol(s): N0177

Schiff D, Sarkaria J, Decker P, Buckner J, Galanis E, Dancey J, Wiesenfeld M, Jaeckle K: Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572. International Conference on Brain Tumor Research and Therapy, Hokkaido, Japan, June, 2008.
Protocol(s): N0572

RTOG

Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 2008; 26(Suppl):Abst.2006.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32096
Protocol(s): RTOG-98-02

Gastrointestinal Cancer

ACOSOG

DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, von Mehren M, Pisters P, Brennan MF, Ballman KV: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008:Abst.8.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10450
Protocol(s): ACOSOG-Z9000

Picozzi VJ, Abrams RA, Traverso LW, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Decker PA, Pisters PW, Posner MC: ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. J Clin Oncol 2008; 26(Suppl):Abst.4505.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31136
Protocol(s): ACOSOG-Z05031

Picozzi VJ, Abrams RA, Traverso LW, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Decker PA, Pisters PW, Posner MC: ACOSOG Z05031: Initial report of a multicenter, phase II trial of a novel chemoradiation protocol using cisplatin, 5-FU, and alpha-interferon as adjuvant therapy for resected pancreas cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008:Abst.125.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10335
Protocol(s): ACOSOG-Z05031

Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB, Meyers BF: Extent and Quality of Lymphadenectomy in Esophageal Cancer Resection - Review of the American College of Surgeons Oncology Group Z0600 Trial. The Society of Thoracic Surgeons, Fort Lauderdale, Florida, Jan, 2008.
<http://www.sts.org/2008webcast/shows/veeramachaneni/header.jpg>

ACRIN

Galen B: CT Colonography: Science to Practice on the U.S., Helsingør, Denmark, June, 2008.

<http://appliedresearch.cancer.gov/icsn/meetings/2008/>

Protocol(s): ACRIN-6664

CALGB

de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient (pt) ACCENT dataset. J Clin Oncol 2008; 26(Suppl):Abst.4007.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35362

Protocol(s): C89803, NSABP-C-01, NSABP-C-03, NSABP-C-02, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

Jackson NA, Fuchs CS, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Meyerhardt JA: The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. J Clin Oncol 2008; 26(Suppl):Abst.4039.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33374

Protocol(s): C89803

McLeod HL, Owzar K, Kroetz D, Innocenti F, Das S, Friedman P, Giacomini K, Goldberg RM, Venook AP, Ratain MJ: Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203. J Clin Oncol 2008; 26(Suppl):Abst.3513.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31778

Protocol(s): CALGB-80203

Ocean AJ, Niedzwiecki D, Atkins JN, Parker B, O'Neil BH, Lee JW, Wadler S, Goldberg RM: LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402. J Clin Oncol 2008; 26(Suppl):Abst.4109.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35166

Protocol(s): CALGB-80402

O'Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM: A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol 2008; 26(Suppl):Abst.4515.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32729

Protocol(s): CALGB-80603

COG

Malogolowkin MH, Katzenstein HM, Krailo MD, Rowland J, Haas J, Meyers R, Finegold MJ: Complete surgical resection for children with pure fetal histology hepatoblastoma (PFH): A report of the Childrens Oncology Group (COG). J Clin Oncol 2008; 26(Suppl):Abst.10049.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33950

Protocol(s): INT-0098

ECOG

Berlin JD, Powell ME, Su Y, Horton L, Short S, Richmond A, Kauh JS, Staley CA, Mulcahy M, Benson AB: Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates. J Clin Oncol 2008; 26(Suppl):Abst.4592.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30912
Protocol(s): E6202

Burtness BA, Powell ME, Berlin JD, Liles DK, Chapman AE, Mitchell EP, Benson AB: Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results. J Clin Oncol 2008; 26(Suppl):Abst.4642.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33368
Protocol(s): E8200

Kleinberg L, Powell ME, Forastiere AA, Keller S, Anne P, Benson AB: Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol 2008; 26(Suppl):Abst.4532.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31710
Protocol(s): E1201

Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR, Benson AB: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26(Suppl):Abst.4506.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30957
Protocol(s): E4201

Sun W, Powell ME, O'Dwyer P, Ansari RH, Benson AB: A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol 2008; 26(Suppl):Abst.4535.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31775
Protocol(s): E5203

NCCTG

Alberts SR, Donohue JH, Mahoney MR, Nelson GD, Schwarzenberger PO, Kugler JW, Morton RF, Flynn PJ: Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver. J Clin Oncol 2008; 26(Suppl):Abst.15006.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34527
Protocol(s): N014A

de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient (pt) ACCENT dataset. J Clin Oncol 2008; 26(Suppl):Abst.4007.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35362

Protocol(s): NSABP-C-01, NSABP-C-03, NSABP-C-02, NSABP-C-04, NSABP-C-05, C89803, NSABP-C-07, NSABP-C-06

Grothey A, Sargent DJ, Szydlo DW, Zhao X, Campbell M, Goldberg RM, Sloan JA: Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC). ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.334.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10575

Protocol(s): N9741

Kim GP, Haddock M, Foster NR, Bollinger J, Stella PJ, Kugler JW, Alberts SR, Martenson J: Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer. J Clin Oncol 2008; 26(Suppl):Abst.15553.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35888

Protocol(s): N0349

Kim GP, Haddock MG, Foster NR, Bollinger J, Stella PJ, Kugler JW, Alberts SM, Martenson JA: Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.144.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10804

Protocol(s): N0349

Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL: Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 2008; 26(Suppl):Abst.4009.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32445

Protocol(s): N04C7

Sanoff HK, Campbell ME, Pitot HC, Goldberg RM, Sargent DJ: Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741. J Clin Oncol 2008; 26(Suppl):Abst.4018.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34993

Protocol(s): N9741

Sargent DJ, Campbell M, Grothey A, Goldberg RM: Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.446.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10531

Protocol(s): N9741

Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008; 26(Suppl):Abst.4008.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33641

Protocol(s): NCCTG-93-46-55

Sloan JA, Grothey A, Green EM, Zhao C, Campbell M, Szydlo D, Sargent DJ, Goldberg RM: Tumor burden is not related to quality of life in patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.458.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10737

Protocol(s): N9741

Turja JH, Grothey A, Sargent DJ, Szydlo DW, Zhao X, Campbell ME, Goldberg RM, Sloan JA: Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2008; 26(Suppl):Abst.4016.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33508

Protocol(s): N9741

NSABP

Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J Clin Oncol 2008; 26(Suppl):Abst.4006.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30662

Protocol(s): NSABP-C-08

de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient (pt) ACCENT dataset. J Clin Oncol 2008; 26(Suppl):Abst.4007.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35362

Protocol(s): NSABP-C-06, NSABP-C-01, NSABP-C-04, NSABP-C-07, C89803, NSABP-C-05, NSABP-C-02, NSABP-C-03

Lavery I, Hammel J, Cowens J, Clark-Langone K, Hackett J, Baehner F, Yothers G, O'Connell M, Wolmark N: Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.302.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10523

Protocol(s): NSABP-C-06

O'Connell MJ, Yothers G, Paik S, Lavery IC, Cowens JW, Clark-Langone KM, Lopatin M, Hackett JR, Baehner FL, Wolmark N: Relationship between tumor gene expression and recurrence in patients with stage II/III colon cancer treated with surgery + 5-FU/LV in NSABP C-06: Consistency of results with two other independent studies. ASCO Gastrointestinal Cancer Symposium, Orlando, Florida, Jan, 2008. Abst.301.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10623

Protocol(s): NSABP-C-07

Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O'Connell MJ, Yothers G: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 2008; 26(Suppl):Abst.LBA4005.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30044

Protocol(s): NSABP-C-07

Yothers G, Land SR, Ganz PA, Fehrenbacher L, Giguere JK, Wickerham DL, Ko CY: Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01. J Clin Oncol 2008; 26(Suppl):Abst.9575.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35795

Protocol(s): NSABP-LTS-01, NSABP-C-07

RTOG

Dawson DW, Garcia M, Dawson N, Tze S, Seligson D, Farrell J, Kurdistani S, Guha C: Cellular patterns of histone modifications predict clinical prognosis in resectable pancreatic adenocarcinoma: results from RTOG study 9704 Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.5560.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={915A7C40-23A5-4C4C-B908-3C48ED727271}&SKey={968421CB-8CD7-4729-A5DB-DD80813AA804}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): RTOG-97-04

Wong SJ, Winter K, Meropol NJ, Anne R, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Willett CG: RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol 2008; 26(Suppl):Abst.4021.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31098

Protocol(s): RTOG-0247

SWOG

Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ, Blanke CD: Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group study. ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2008. Abst.96.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10023

Protocol(s): S0415

Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ, Blanke CD: Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. *J Clin Oncol* 2008; 26(Suppl):Abst.4536.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30811

Protocol(s): S0415

Holmes RS, Rankin C, Makar KW, Benedetti JK, Smalley SR, Blanke CD, Lenz HJ, Ulrich CM: Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (SWOG 9304). Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.4797.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={D1CDA76A-ED17-4A97->

Protocol(s): INT-0144/SWOG-9304

Ulrich CM, Rankin C, Holmes RS, Makar KW, Benedetti JK, Smalley SR, Blanke CD, Lenz H: Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (SWOG 9304). ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2008. Abst.309.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10366

Protocol(s): INT-0144/SWOG-9304

Zhang W, Rankin C, Nagashima F, Ulrich CM, Holmes RS, Makar KW, Benedetti JK, Blanke CD, Smalley SR, Lenz HJ: Pharmacogenetic analysis of stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). ASCO Gastrointestinal Cancers Symposium, Orlando, Florida, Jan, 2008. Abst.300.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10495

Protocol(s): INT-0144/SWOG-9304

Zhang W, Rankin CJ, Danenberg KD, Benedetti JK, Danenberg PV, Ulrich CM, Holmes RS, Makar KW, Blanke CD, Smalley SR, Lenz HJ: An update of pharmacogenetic analysis of adjuvant rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). *J Clin Oncol* 2008; 26(Suppl):Abst.4115.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33652

Protocol(s): INT-0144/SWOG-9304

Genitourinary Cancer

CALGB

Halabi S, Ou S, Vogelzang NJ, Small EJ: Is progression-free survival a predictor of overall survival in men with castration-resistant prostate cancer (CRPC)? ASCO Genitourinary Cancers Symposium, San Francisco, California, Feb, 2008. Abst.150.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20388

Protocol(s): CALGB-90006, CALGB-9182, CALGB-90004, CALGB-9680, CALGB-99813, CALGB-9583, CALGB-9480, CALGB-9181, CALGB-9780

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena D, Ou S, Taylor J, Tanguay S, Dutcher J, Small EJ: CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium, San Francisco, California, Feb, 2008. Abst.350.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20357

Protocol(s): CALGB-90206

ECOG

Chen Y, Wilding G, Gee J, DiPaola RP, Pins M, Carducci MA, Stein MN, Bublely G, Liu G: A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA. J Clin Oncol 2008; 26(Suppl):Abst.5170.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35359

Protocol(s): E5803

Dreicer R, Li N, Stein MN, DiPaola RP, Eleff M, Roth BJ, Wilding G: Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26(Suppl):Abst.5083.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31628

Protocol(s): E1804

Liu G, Chen Y, Pins M, Carducci M, Gee J, DiPaola R, Wilding G: E5803: A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA. J Clin Oncol 2008; (Suppl):Abst.169.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20372

Protocol(s): E5803

Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G: E3803: Updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008; 26(Suppl):Abst.5070.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31403

Protocol(s): E3803

RTOG

Smith MR, Kyoungwha B, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU: Diabetes and mortality in men with locally advanced prostate cancer: analyses of RTOG 92-02. J Clin Oncol 2008; 26(Suppl):Abst.5013.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33550

Protocol(s): RTOG-92-02

SWOG

Conlon S, Tangen CM, Flanigan RC, Crawford ED, Lara PN: Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949. ASCO Genitourinary Cancers Symposium, San Francisco, California, Feb, 2008. Abst.347.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20243

Protocol(s): SWOG-8949

Conlon S, Tangen CM, Flanigan RC, Crawford ED, Lara PN: Predictors of survival in advanced renal cell carcinoma (RCC): Long-term results from Southwest Oncology Group trial S8949. *J Clin Oncol* 2008; 26(Suppl):Abst.5042.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32157

Protocol(s): SWOG-8949

Goldman B, Hussain M, Tangen C, Higano C, Petrylak D, Vogelzang NJ, Crawford ED: Prostate-specific antigen progression (PSA-P) as a predictor of overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916. *ASCO Genitourinary Cancers Symposium*, San Francisco, California, Feb, 2008. Abst.165.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20310

Protocol(s): S9916, INT-0162/SWOG-9346

Hussain MH, Goldman B, Tangen CM, Higano CS, Petrylak DP, Crawford ED: Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916. *J Clin Oncol* 2008; 26(Suppl):Abst.5015.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32059

Protocol(s): S9916, INT-0162/SWOG-9346

Lara PN, Goldman B, deVere White R, Tangen CM, Smith DC, Wood D, Hussain MH, Crawford ED: A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG). *J Clin Oncol* 2008; 26(Suppl):Abst.5022.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32346

Protocol(s): S0219

Pan C, Hussey M, Lara PN, Mack PC, Nagle R, Dutcher JP, Samlowski WE, Clark J, Gordon MS, Crawford ED: Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317. *J Clin Oncol* 2008; 26(Suppl):Abst.5051.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31466

Protocol(s): S0317

Gynecologic Cancer

GOG

Alvarez-Secord A, Rubatt JM, Darcy KM, Hutson A, Bean S, Havrilesky LJ, Grace LA, Berchuck A: Prognostic relevance of microvessel density in previously untreated, advanced stage epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2008; 108(3):Abst.5 S20.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0114

Bodurka DC, Deavers M, Tian C, Sun CC, Ozols RF, Gershenson DM: Ancillary study of GOG 158: Survival based on reclassification to a two-tier grading system for serous carcinoma of the ovary. *Gynecologic Oncology* 2008; 108(3):Abst.71 S33.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0158

Chan JK, Fleming G, Zhang M, Tian C, Kapp DS, Monk BJ, Herzog T, Bell J: The potential benefit of six versus three cycles of chemotherapy in subsets of women with high-risk early-stage epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. *Gynecologic Oncology* 2008; 108(3):Abst.4 S3.

<http://www.sgo.org/content.aspx?id=886>

<http://www.medpagetoday.com/MeetingCoverage/SGO/tb/8697>

Protocol(s): GOG-0157

Chan JK, Teoh D, Tian C, Kapp DS, Monk BJ, Herzog T, Bell J: Survival after recurrence is poor for women with early-stage high risk ovarian cancer - a Gynecologic Oncology Group study. *Gynecologic Oncology* 2008; 108(3):Abst.63 S29.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0157

Farley JH, Maxwell GL, Tian C, Rose GS, Brown CL, Thigpen JT, Gallion HH, Birrer MJ: Chemotherapy intensity and toxicity between African American and Caucasian women with advanced and recurrent endometrial cancer: Experiences from Gynecologic Oncology Group (GOG) clinical trials. *Gynecologic Oncology* 2008; 108(3):Abst.40 S19.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0107

Han E, Burger R, Randall L, Parmakhtiar B, Darcy K, Sill M, Connelly P, Monk B, Fruehauf J: Angiogenesis biomarker expression in recurrent or persistent epithelial ovarian cancer (EOC) and patients with primary peritoneal cancer (PPC) treated with bevacizumab (Bev): A gynecologic oncology group (GOG) study. *Gynecologic Oncology* 2008; 108(3):Abst.44 S21.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0170D

Han ES, Burger R, Darcy KM, Sill MW, Greer BE, Sorosky JI, Fruehauf JP: Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). *J Clin Oncol* 2008; 26(Suppl):Abst.5577.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36264

Protocol(s): GOG-0170D

Homesley H, Filiaci V, Gibbons SK, Long HD, Spirtos N, Morris R, DeGeest K, Lee R, Montag A: Randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. *Gynecologic Oncology* 2008; 108(3):Abst.1 S2.

<http://www.sgo.org/content.aspx?id=886>

<http://www.caring4cancer.com/go/ovarian/news?NewsItemId=42025>

Protocol(s): GOG-0184

Krivak TC, Darcy KM, Tian C, Baysal BE, Armstrong DK, Gallion HH, DeLoia JA: Relationship between polymorphisms in codon 118 and C8092A in ERCC1 and clinical outcome in optimally-resected, stage III epithelial ovarian cancer treated with intraperitoneal or intravenous cisplatin and paclitaxel: A gynecologic oncology group study. *Gynecologic Oncology* 2008; 108(3):Abst.277 S122.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0172

Krivak TC, Darcy KM, Tian C, Bookman MA, Baysal BA, Gallion HH, Ambrosone CB, DeLoia JA: Relationship between ERCC1 polymorphisms, disease progression, and survival in GOG0182, a Gynecologic Oncology Group phase III trial of platinum-based chemotherapy in women with advanced stage epithelial ovarian or primary peritoneal cancer. J Clin Oncol 2008; 26(Suppl):Abst.5540.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32581

Protocol(s): GOG-0182

Krivak TC, Tian C, Armstrong D, Rose GS, Maxwell GL: A comparison of serum CA125 antigen normalization patterns in patients with optimal stage III ovarian carcinoma treated with intraperitoneal (IP) vs intravenous (IV) cisplatin/paclitaxel: a Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108(3):Abst.23 S11.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0172

Kunos C, Simpkins F, Gibbons H, Tian C, Homesley HD: Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes: An update of a Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108(3):Abst.5 S4.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-37

Matei D, Sill MW, DeGeest K, Bristow RE: Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008; 26(Suppl):Abst.5537.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33281

Protocol(s): GOG-0170F

Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology 2008; 108(3):Abst.207 S92.

<http://www.ncbi.nlm.nih.gov/pubmed/18455781?dopt=Abstract>

Protocol(s): GOG-0127T

Miller DS, Blessing JA, Krasner CN, Mannel RJ: A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group. J Clin Oncol 2008; 26(Suppl):Abst.5524.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31946

Protocol(s): GOG-0126Q

Monk B, Sill M, Burger RA, Gray HJ, Buekers TE, Roman LD: Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108(3):Abst.45 S21.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0227C

Monk BJ, Sill M, McMeekin DS, Cohn DE, Ramondetta L, Boardman CH, Benda J: A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. J Clin Oncol 2008; 26(Suppl):Abst.LBA5504.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35634

Protocol(s): GOG-0204

Osborne R, Filiaci V, Schink J, Mannel R, Lage J, Alvarez-Secord A, Kelly J, Provencher D, Schilder J, Miller D: A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia. Gynecologic Oncology 2008; 108(3):Abst.2 S2.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0174

Randall LM, Monk BJ, Darcy KB, Tian C, Burger RA, Liao S, Peters WA, Stock RA, Fruehauf JP: Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108(3):Abst.46 S22.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-9911

Tewari D, Chunqiao T, Armstrong DK, Markman M, Herzog TJ, Monk BJ: The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials. J Clin Oncol 2008; 26(Suppl):Abst.5549.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32740

Protocol(s): GOG-0114

vonGruenigen VE, Gil K, Huang H, Gibbons HE, Rose P, Armstrong D, Cella D, Wenzel L: Quality of life in ovarian cancer patients during adjuvant chemotherapy: A GOG multivariate item analysis. Gynecologic Oncology 2008; 108(3):Abst.5 S28.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0152

Waggoner SE, Darcy KM, Tian C, Lanciano R: Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2008; 108(3):Abst.211 S94.

<http://www.sgo.org/content.aspx?id=886>

Protocol(s): GOG-0165

Wenzel LB, Huang H, Cella D, Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH, Benda J: Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: A gynecologic oncology group (GOG) study. J Clin Oncol 2008; 26(Suppl):Abst.5529.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32608

Protocol(s): GOG-0204

Williams S, Monahan P, Miller A, Gershenson DM, Zhao Q, Cella D, Champion V, Matei D: Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors. J Clin Oncol 2008; 26(Suppl):Abst.9551.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31141

Protocol(s): GOG-9901

NCIC Clinical Trials Group

Biagi JJ, Oza AM, Grimshaw R, Ellard SL, Lee U, Sederias J, Ivy SP, Eisenhauer EA: A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185. *J Clin Oncol* 2008; 26(Suppl):Abst.5522.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32681
 Protocol(s): NCIC-185

Oza AM, Elit L, Provencher D, Biagi J, Panasci L, Sederias J, Dancey JE, Tsao MS, Eisenhauer EA: A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. *J Clin Oncol* 2008; 26(Suppl):Abst.5516.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34670
 Protocol(s): NCIC-160

Head and Neck Cancer

ECOG

Langer CJ, Lee JW, Patel UA, Shin DM, Argiris AE, Quon H, Ridge JA, Forastiere AA: Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). *J Clin Oncol* 2008; 26(Suppl):Abst.6006.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31585
 Protocol(s): E3303

Leukemia, Myelodysplasia, and Transplantation

CALGB

Langer C, Maharry K, Mrózek K, Paschka P, Whitman SP, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD: Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study. *J Clin Oncol* 2008; 26(Suppl):Abst.7011.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31443
 Protocol(s): CALGB-19808, CALGB-9621

Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, Bloomfield CD, Larson RA, Sher D: High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710). *J Clin Oncol* 2008; 26(Suppl):Abst.7002.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33927
 Protocol(s): C9710

COG

Borowitz MJ, Devidas M, Hunger SP, Carroll WL, Linda S, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM: Prognostic significance of end consolidation minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group (COG). J Clin Oncol 2008; 26(Suppl):Abst.10000.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31223

Protocol(s): POG-9905, POG-9906, POG-9904

Dhall G, Robison NJ, Rubin JI, Sather HN, Gaynon PS, Seibel NL, Ettinger LJ: Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group Study CCG-1961. J Clin Oncol 2008; 26(Suppl):Abst.10021.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32197

Protocol(s): CCG-1961

Dunsmore K, Devidas M, Borowitz MJ, Winick N, Hunger SP, Carroll WL, Camitta BM: Nelarabine in combination with intensive modified BFM AALL00P2: A pilot study for the treatment of high risk T-ALL a report from the Children's Oncology Group. J Clin Oncol 2008; 26(Suppl):Abst.10002.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35532

Protocol(s): AALL00P2

LaFiura KM, Edwards H, Dombkowski A, Chang M, Taub JW, Matherly LH, Ravindranath Y, Ge Y: The role of AML1 in gene expression and chemotherapy sensitivity in pediatric t(8;21) acute myeloid leukemia: A report from the children's oncology group. Proc Am Assoc Cancer Res 2008; 49():Abst.3015.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={B7AF77BF-9461-46AC-9905-2C47C189F1E6}&SKey={4BC70677-BF02-4D3B-B984-B95D8FA3EED0}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): POG-9421

Maloney K, Carroll WL, Carroll A, Devidas M, Hunger SP, Martin PL, Willman CL, Winick N, Whitlock J, Camitta BM: Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group (COG) study P9900. J Clin Oncol 2008; 26(Suppl):Abst.10003.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33468

Protocol(s): POG-9900

Shankar SM, Chen L, Zhou T, Krailo MD, Reaman G, Bhatia S: Risk of therapy related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in children exposed to alkylating agents, anthracyclines, platinum compounds and epipodophyllotoxins: a report from Children's Oncology Group (COG). J Clin Oncol 2008; 26(Suppl):Abst.10005.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31359

Protocol(s): Multiple Trials

Lymphoma and Plasma Cell Disorders

CALGB

His E, Jung S, Lai R, Johnson J, Cook J, Jones D, DeVos S, Cheson BD, Damon LE, Said J: Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study. *J Clin Oncol* 2008; 26(Suppl):Abst.8560.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32410
 Protocol(s): CALGB-59909

ECOG

Levine AM, Lee J, Kaplan L, Liebes LF, Sparano JA: Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. *J Clin Oncol* 2008; 26(Suppl):Abst.8527.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33930
 Protocol(s): AMC-034

Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV, Abonour R, Siegel DS, Katz M, Greipp PR: Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome. *J Clin Oncol* 2008; 26(Suppl):Abst.8504.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36097
 Protocol(s): E4A03

NCCTG

Micallef I, Maurer M, Nikcevich D, Cannon M, Moore D, Kurtin P, Schaefer E, Witzig T: Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. International Lymphoma Conference, Lugano, Switzerland, Jun, 2008:Abst.257.
<https://www.lymphcon.ch/>
 Protocol(s): N0489

Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore DF, Kurtin P, Witzig TE: A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *J Clin Oncol* 2008; 26(Suppl):Abst.8500.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31220
 Protocol(s): N0489

SWOG

Zonder JA, Crowley JJ, Bolejack V, Hussein MA, Moore DF, Whittenberger BF, Abidi MH, Durie BG, Barlogie B: A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. *J Clin Oncol* 2008; 26(Suppl):Abst.8521.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36278

Protocol(s): S0232

Lung Cancer

CALGB

Govindan R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE: A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407--Early evaluation of feasibility and toxicity. *J Clin Oncol* 2008; 26(Suppl):Abst.7518.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36075

Protocol(s): CALGB-30407

Lamont EB, Archer LE, Lan L, Vokes EE, McNeil BJ, Keating NL, Landrum M: Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: analyses from 10 CALGB lung cancer trials. *J Clin Oncol* 2008; 26(Suppl):Abst.6517.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33570

Protocol(s): Multiple Trials

ECOG

Aisner J, Dahlberg S, Rodgers JS, Aisner SC, Schiller JH: Interferon alpha + 13-cis-retinoic acid modulation of BCL-2 + paclitaxel for recurrent SCLC. *J Clin Oncol* 2008; 26(Suppl):Abst.19048.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33917#

Protocol(s): E6501

Archer V, Reck M, Sandler AB, Johnson DH, Kong G, Strickland DK, Bennouna J: Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. *J Clin Oncol* 2008; 26(Suppl):Abst.8114.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35210

Protocol(s): E4599

Dang TP, Salmon JS, Chen H, Chen S, Lee JW, Sandler AB, Herbst RS, Brahmer J, Carbone DP, Shyr Y: Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone. *J Clin Oncol* 2008; 26(Suppl):Abst.11014.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32202

Protocol(s): E3503

Sandler AB, Hirsh V, Reck M, Archer V, Samant MK, Wang L, Strickland DK, Dimery I, Johnson DH: Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(Suppl):Abst.8074.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34195

Protocol(s): E4599

Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP: A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008; 26(Suppl):Abst.8014.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31135

Protocol(s): E2501

NCCTG

Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Gandara DR, Allen Ziegler KL, Stella PJ, Rowland KM, Schild SR, Zinner RG: A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. J Clin Oncol 2008; 26(Suppl):Abst.8080.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33284

Protocol(s): N0426

Jett JR, Bernath AM, Foster NR, Molina JR, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM, Fitch TR, Adjei AA: Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study. J Clin Oncol 2008; 26(Suppl):Abst.8066.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32144

Protocol(s): N0423

NCIC Clinical Trials Group

Jang RW, Le Maître A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, Leighl NB: A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial. J Clin Oncol 2008; 26(Suppl):Abst.6535.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30437

Protocol(s): JBR10

Reiman T, Seve P, Vataire A, Dunant A, Rosell R, Graziano S, Seymour L, Pirker R, Lai R: Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials. J Clin Oncol 2008; 26(Suppl):Abst.7506.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31961

Protocol(s): CALGB-150802, JBR10

Tsao MS, Zhu C, Ding K, Strumpf D, Pintilie M, Meyerson M, Seymour L, Jurisica I, Shepherd FA: A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol 2008; 26(Suppl):Abst.7510.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32591

Protocol(s): JBR10

Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Shepherd FA: The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Clin Oncol 2008; 26(Suppl):Abst.8054. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32591
Protocol(s): JBR10

RTOG

Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella FV, Werner-Wasik M, Doescher P, Choy H, Komaki R: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008; 26(Suppl):Abst.7516. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36161
Protocol(s): RTOG-0324

Olsen CC, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, Robert F, Choy H, Blumenschein GR, Hirsch FR: RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-- Association between EGFR gene copy number and patients' outcome. J Clin Oncol 2008; 26(Suppl):Abst.7607. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30610
Protocol(s): RTOG-0324

SWOG

Gitlitz BJ, Glisson BS, Moon J, Reimers H, Gandara DR: Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial. J Clin Oncol 2008; 26(Suppl):Abst.8039. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31238
Protocol(s): S0435

Le Q, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar L, Crowley JJ, Moore DF, Gandara DR: SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC). J Clin Oncol 2008; 26(Suppl):Abst.7523. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30235
Protocol(s): S0222

Natale RB, Lara PN, Chansky K, Crowley JJ, Jett JR, Carleton JE, Kuebler JP, Lenz HJ, Mack PC, Gandara DG: S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 2008; 26(Suppl):Abst.7512. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35772
Protocol(s): S0124

West H, Chansky K, Franklin WA, Hirsch FR, Crowley JJ, Lau DH, Gandara DR: Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. J Clin Oncol 2008; 26(Suppl):Abst.8047.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30827
 Protocol(s): S0126

Melanoma/Skin Cancers

NCCTG

Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN: A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. J Clin Oncol 2008; 26(Suppl):Abst.9044.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34028
 Protocol(s): N057E

SWOG

Clark J, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva D, Liu PY, Thompson JA, Sondak VK: Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. J Clin Oncol 2008; 26(Suppl):Abst.9007.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30355
 Protocol(s): S0508

Sarcoma/Bone and Soft Tissue Cancers

COG

Chou AJ, Kleinerman E, D. Krailo M, Betcher D, Healey J, Nadel H, Nieder M, Weiner M, Wells RJ, Meyers PA: Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. J Clin Oncol 2008; 26(Suppl):Abst.10018.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31748
 Protocol(s): INT-0133

Womer RB, West DC, Krailo MD, Dickman PS, Pawel B: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008; 26(Suppl):Abst.10504.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30718
 Protocol(s): AEWS0031

RTOG

Kane JM, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, DeLaney TF, Wang D, Curran WJ, Eisenberg BL: RTOG 0330: A pilot phase II study of preoperative radiation therapy/thalidomide for low-grade primary soft tissue sarcoma or preoperative MAID/thalidomide/radiation therapy for high/intermediate grade primary soft tissue sarcoma of the extremity or body wall. J Clin Oncol 2008; 26(Suppl):Abst.10536.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33436

Protocol(s): RTOG-0330

SWOG

Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008; 26(Suppl):Abst.10532.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32180

Protocol(s): S0505

Schuetze SM, Rankin CA, Rubin BP, Butrynski JE, Borden EC: SWOG0345: Prospective phase II trial of imatinib in dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2008; 26(Suppl):Abst.10580.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30618

Protocol(s): S0345

Other Cancer

CALGB

Ferrans CE, Ryan C, Archer LE, Freels S, Lan L, Paskett E, Molokie R, Hurd DD, Kornblith AB: Factors contributing to cancer screening in African Americans. J Clin Oncol 2008; 26(Suppl):Abst.6514.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35926

Protocol(s): Multiple Trials

COG

Aplenc R, Strauss LC, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Blaney SM, Adamson PC: Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group Phase I Consortium. J Clin Oncol 2008; 26(Suppl):Abst.3591.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35066

Protocol(s): ADVL0516

DuBois SG, Shusterman S, Ingle AM, Baruchel S, Stempak D, Sun J, Ivy SP, Glade-Bender J, Blaney SM, Adamson PC: A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2008; 26(Suppl):Abst.3561.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33721

Protocol(s): ADVL0612

Jacobs S, Fox B, Krailo MD, Hartley G, Navid F, Wexler L, Blaney SM, Frank B, Adamson PC, Widemann BC: Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. J Clin Oncol 2008; 26(Suppl):Abst.10026.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35480

Protocol(s): ADVL0524

Kreissman SG, Villablanca JG, Seeger RC, Grupp SA, London WB, Maris JM, Park JR, Cohn SL, Matthay KK, Reynolds CP: A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. J Clin Oncol 2008; 26(Suppl):Abst.10011.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30386

Protocol(s): Multiple Trials

Mosse YP, Laudenslager M, Longo L, Perri P, Tonini GP, George R, Hanna M, Greulich H, Meyerson M, Look AT, McConville CM, Laureys G, Speleman F, Hou C, Kim C, Hakonarson H, Brodeur GM, Rappaport E, Devoto M, Maris JM: Identification of ALK as the major familial neuroblastoma predisposition gene. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.LB-237.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={D9927C57-B40A-4868-82F3-165E6167B1AB}&SKey={229CE465-0259-45DC-ADED-F54D81CF3D05}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Protocol(s): ANBL00B1

Russell H, Cairo MS, Blaney SM, Adamson PC, Ingle AM, Berg S: Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children's Oncology Group phase I consortium study. J Clin Oncol 2008; 26(Suppl):Abst.13532.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35977

Protocol(s): ADVL0319

Shusterman S, London WB, Gillies SD, Hank JA, Voss S, Seeger RC, Hecht T, Reisfeld RA, Maris JM, Sondel PM: Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. J Clin Oncol 2008; 26(Suppl):Abst.3002.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32009

Protocol(s): ANBL0322

Soud A, Dubowy RL, Greenwald Triplett D, Ingle AM, Sun J, Blaney SM, Adamson PC: Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A Children's Oncology Group phase I consortium study. J Clin Oncol 2008; 26(Suppl):Abst.10014.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30871

Protocol(s): ADVL0517

ECOG

Lemma GL, Loehrer PJ, Lee JW, Langer CJ, Tester WJ, Johnson DH: A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008; 26(Suppl):Abst.8018.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34143

Protocol(s): E1C99

NCCTG

Barton DL, LaVasseur B, Sloan JA, Stella PJ, Flynn K, Dyar M, Dakhil SR, Atherton PJ, Diekmann B, Loprinzi CL: A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9. *J Clin Oncol* 2008; 26(Suppl):Abst.9538.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33848
Protocol(s): N05C9

Burger K, Atherton PJ, Schaefer PL, Halyard MY, Sloan JA: Compliance issues in completion of patient-reported outcomes in a series of NCCTG/Mayo clinical trials. *J Clin Oncol* 2008; 26(Suppl):Abst.17506.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36062
Protocol(s): Multiple Trials

Campbell ME, Mandrekar SJ, Hillman SL, Goldberg RM, Adjei AA, Pitot HC, Rowland KM, Grothey A, Buckner JC, Sargent DJ: What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings. *J Clin Oncol* 2008; 26(Suppl):Abst.6520.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33528
Protocol(s): N0026, N9841, N9741

Dueck AC, Atherton PJ, Liu H, Hines SL, Loprinzi CL, Perez EA, Tan AD, Burger K, Zhao X, Diekmann B, Sloan JA: Endpoint comparison for osteoporosis assessment in cancer control studies (N02C1 and N03CC). *J Clin Oncol* 2008; 26(Suppl):Abst.6627.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36036
Protocol(s): N03CC, N02C1

Holtan SG, Foster NR, Erlichman CE, Aubry M, Ames MM, Safgren S, Steen PD, Morton RF, Graham D, Goetz MP: Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial. *J Clin Oncol* 2008; 26(Suppl):Abst.13525.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32031
Protocol(s): N004E

Liu H, Tan AD, Grothey A, Schaefer PL, Buckner JC, Loprinzi CL, Morton RF, Sloan JA: Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts). *J Clin Oncol* 2008; 26(Suppl):Abst.9534.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33864
Protocol(s): N05C3, N9741, N9841, N01C3, N00C3

Loprinzi CL, Sloan JA, Stearns V, Diekmann B, Novotny PJ, Kimmick G, Gordon P, Pandya KJ, Guttuso T, Reddy S: Newer antidepressants and gabapentin for hot flashes: An individual subject pooled analysis. *J Clin Oncol* 2008; 26(Suppl):Abst.9537.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35366
Protocol(s): Multiple Trials

Tan AD, Novotny PJ, Kaur JS, Buckner JC, Schaefer PL, Stella PJ, Kuebler JP, Sloan JA: A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. *J Clin Oncol* 2008; 26(Suppl):Abst.9515.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33656

Protocol(s): Multiple Trials

Zhao X, Sloan JA, Hartung A, Buckner JC, Sargent DJ, Stella PJ: The value of preliminary data in power specifications based upon 64 NCCTG phase II/III treatment trials. *J Clin Oncol* 2008; 26(Suppl):Abst.6538.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36076

Protocol(s): Multiple Trials

RTOG

Bae K, Watkins-Bruner D, Yan Y, Coyne J, Movsas B: Evaluation of missing quality of life assessments patterns in radiation therapy oncology group (RTOG) trials. *J Clin Oncol* 2008; 26(Suppl):Abst.20510.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34691

Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Aplenc R, Strauss LC, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Blaney SM, Adamson PC: Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: A report from the Children's Oncology Group Phase I Consortium. *J Clin Oncol* 2008; 26(Suppl):Abst.3591.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35066

Biagi JJ, Oza AM, Grimshaw R, Ellard SL, Lee U, Sederias J, Ivy SP, Eisenhauer EA: A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185. *J Clin Oncol* 2008; 26(Suppl):Abst.5522.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32681

Carol H, Morton CL, Houghton PJ, Maris JM, Friedman HS, Keir ST, Gorlick G, Kolb EA, Smith MA, Lock RB: Pediatric Preclinical Testing Program (PPTP) evaluation of the topoisomerase I inhibitor topotecan. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.2996.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={9EC3ABA8-E267-4414-AB41-3ADA1AFBDDA1}&SKey={4BC70677-BF02-4D3B-B984-B95D8FA3EED0}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

Dhall G, Robison NJ, Rubin JI, Sather HN, Gaynon PS, Seibel NL, Ettinger LJ: Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group Study CCG-1961. *J Clin Oncol* 2008; 26(Suppl):Abst.10021.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32197

DuBois SG, Shusterman S, Ingle AM, Baruchel S, Stempak D, Sun J, Ivy SP, Glade-Bender J, Blaney SM, Adamson PC: A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: A Children's Oncology Group Phase I Consortium study. *J Clin Oncol* 2008; 26(Suppl):Abst.3561.

http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33721

Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM: A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. *J Clin Oncol* 2008; 26(Suppl):Abst.5521.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34030

Houghton PJ, Morton CL, Maris JM, Courtright J, Carol H, Lock RB, Friedman HS, Keir ST, Gorlick R, Kolb EA, Reynolds CP, Kang M, Smith MA: Pediatric preclinical testing program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008:Abst.2997.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={E7A6AD18-83B9-4011-9567-03D9C9390384}&SKey={4BC70677-BF02-4D3B-B984-B95D8FA3EED0}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

McGregor LM, Spunt SL, Santana VM, Stewart CF, Ward DA, Wu J, Watkins A, Ivy SP, Furman WL, Fouladi M: A phase I study of oxaliplatin and etoposide in pediatric patients with refractory solid tumors. *J Clin Oncol* 2008; 26(Suppl):Abst.10024.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31759

Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ: Molecular characterization of the Pediatric Preclinical Testing Program (PPTP) models. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.1629.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={80A1FF91-9A03-40D2-A8DE-063B3CB0DA52}&SKey={FB39C230-F87C-45FF-9940-0541372E9491}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

O'Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM: A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. *J Clin Oncol* 2008; 26(Suppl):Abst.4515.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32729

Oza AM, Elit L, Provencher D, Biagi J, Panasci L, Sederias J, Dancey JE, Tsao MS, Eisenhauer EA: A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. *J Clin Oncol* 2008; 26(Suppl):Abst.5516.

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34670

Schiff D, Sarkaria J, Decker P, Buckner J, Galanis E, Dancey J, Wiesenfeld M, Jaeckle K: Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572. International Conference on Brain Tumor Research and Therapy, Hokkaido, Japan, Jun, 2008.

Smith MA, Morton C, Maris JM, Courtright J, Kolb EA, Gorlick R, Carol H, Lock RB, Friedman HS, Keir ST, Kang M, Reynolds CP, Houghton PJ: Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886). Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, Apr, 2008: Abst.2998.

<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={ABC14D83-0E12-47C1-B31B-55B6D804BBA8}&SKey={4BC70677-BF02-4D3B-B984-B95D8FA3EED0}&MKey={9EE8A282-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}>

DCTD and DCP Activities

Scientific

Dr. J. Zujewski: CTEP scientific liaison: TBCI Intergroup and Survivorship Meeting. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, Jun, 2008.

Dr. J. Zujewski: Presenter: Harmonization of endpoints and elements of data collection. Breast International Group - North America Breast Cancer Cooperative Groups Collaboration Meeting, Bruges, Belgium, Apr, 2008.

Dr. J. Zujewski: Planning Committee Member: BIG-TBCI-NSABP International Meeting. Breast International Group - North America Breast Cancer Cooperative Groups Collaboration Meeting, Bruges, Belgium, Apr, 2008.

Dr. J. Zujewski: Presenter: Translational research & prioritization of projects. Breast International Group - North America Breast Cancer Cooperative Groups Collaboration Meeting, Bruges, Belgium, Apr, 2008.

Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.